Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Mohamad Mohty, Hermann Einsele et al.|Bone Marrow Transplantation|2024Cited by 15
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Trials|2021Cited by 7
Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Research Square|2021Cited by 0